Literature DB >> 29772441

Six2 is negatively correlated with good prognosis and decreases 5-FU sensitivity via suppressing E-cadherin expression in hepatocellular carcinoma cells.

Jian-Wang Li1, Chun-Zhen Huang2, Jian-Hua Li3, Jian-Hua Yuan2, Qiong-Hui Chen2, Wei-Fang Zhang2, Zhen-Sheng Xu2, Ying-Ping Liu2, Yong Li4, Mei-Xiao Zhan4, Li-Gong Lu5.   

Abstract

This work aims to study the roles and related mechanisms of six2 in 5-FU sensitivity of hepatocellular carcinoma (HCC) cells. KM-Plotter analysis showed that HCC patients with higher six2 expression levels had shorter overall survival. Six2 expression was higher in clinical HCC tissues than in normal tissues, and was negatively correlated with E-cadherin expression. Additionally, six2 overexpression decreased the sensitivity of HCC cells to 5-Fu, characterized as attenuating 5-FU-induced cell apoptosis and downregulation of cell viability, and promoted HCC cells stemness. Mechanistically, six2 overexpression repressed E-cadherin expression via stimulating promoter methylation of the E-cadherin. And E-cadherin overexpression rescued six2-induced decrease of 5-FU sensitivity and promotion on HCC cells stemness. Therefore, our results suggest that Six2 is negatively correlated with good prognosis and decreases 5-FU sensitivity via suppressing E-cadherin expression in HCC cells.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  5-FU; E-cadherin; Hepatocellular carcinoma; Methylation; Six2

Mesh:

Substances:

Year:  2018        PMID: 29772441     DOI: 10.1016/j.biopha.2018.05.032

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  2 in total

1.  Six2 promotes non-small cell lung cancer cell stemness via transcriptionally and epigenetically regulating E-cadherin.

Authors:  Huaying Hou; Xiaoming Yu; Ping Cong; Yong Zhou; Ying Xu; Yuhua Jiang
Journal:  Cell Prolif       Date:  2019-04-22       Impact factor: 6.831

2.  Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC.

Authors:  Yanli Yao; Yujue Wang; Lan Chen; Zhen Tian; Guizhu Yang; Rui Wang; Chong Wang; Qi Wu; Yaping Wu; Jiamin Gao; Xindan Kang; Shengzhong Duan; Zhiyuan Zhang; Shuyang Sun
Journal:  Signal Transduct Target Ther       Date:  2022-03-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.